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Phosphodiesterase 10A (PDE10A) plays a central role in striatal
signaling and is implicated in several neuropsychiatric disorders,
such as movement disorders and schizophrenia. We performed
initial brain kinetic modeling of the novel PDE10A tracer 18F-JNJ-
42259152 (2-[[4-[1-(2-18F-fluoroethyl)-4-(4-pyridinyl)-1H-pyrazol-3-
yl]phenoxy]methyl]-3,5-dimethyl-pyridine) and studied test–retest
reproducibility in healthy volunteers. Methods: Twelve healthy vol-
unteers (5 men, 7 women; age range, 42–77 y) were scanned dy-
namically up to 135 min after bolus injection of 172.56 10.3 MBq of
18F-JNJ42259152. Four volunteers (2 men, 2 women) underwent
retest scanning, with a mean interscan interval of 37 d. Input func-
tions and tracer parent fractions were determined using arterial
sampling and high-performance liquid chromatography analysis.
Volumes of interest for the putamen, caudate nucleus, ventral stria-
tum, substantia nigra, thalamus, frontal cortex, and cerebellum were
delineated using individual volumetric T1 MR imaging scans. One-
tissue (1T) and 2-tissue (2T) models were evaluated to calculate
total distribution volume (VT). Simplified models were also tested
to calculate binding potential (BPND), including the simplified refer-
ence tissue model (SRTM) and multilinear reference tissue model,
using the frontal cortex as the optimal reference tissue. The stability
of VT and BPND was assessed down to a 60-min scan time.
Results: The average intact tracer half-life in blood was 90 min.
The 2T model VT values for the putamen, caudate nucleus, ventral
striatum, substantia nigra, thalamus, frontal cortex, and cerebellum
were 1.54 6 0.37, 0.90 6 0.24, 0.64 6 0.18, 0.42 6 0.09, 0.35 6
0.09, 0.30 6 0.07, and 0.36 6 0.12, respectively. The 1T model
provided significantly lower VT values, which were well correlated
to the 2T VT. SRTM BPND values referenced to the frontal cortex
were 3.45 6 0.43, 1.78 6 0.35, 1.10 6 0.31, and 0.44 6 0.09 for the
respective target regions putamen, caudate nucleus, ventral stria-
tum, and substantia nigra, with similar values for the multilinear
reference tissue model. Good correlations were found for the target
regions putamen, caudate nucleus, ventral striatum, and substantia
nigra between the 2T-compartment model BPND and the SRTM
BPND (r5 0.57, 0.82, 0.70, and 0.64, respectively). SRTM BPND using
a 90- and 60-min acquisition interval showed low bias. Test–retest
variability was 5%–19% for 2T VT and 5%–12% for BPND SRTM.
Conclusion: Kinetic modeling of 18F-JNJ-42259152 shows that PDE10A
activity can be reliably quantified and simplified using a reference
tissue model with the frontal cortex as reference and a 60-min ac-
quisition period.
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Phosphodiesterase 10A (PDE10A) is a dual-substrate enzyme
with a restricted distribution, predominantly in the human brain in
medium spiny neurons of the striatum, the substantia nigra, the
nucleus accumbens and olfactory tuberculum (1), and—to a much
lower extent—the hippocampus and cerebral cortex (1,2). PDE10A
hydrolyzes the important second messengers cyclic adenosine mono-
phosphate (cAMP) and cyclic guanosine monophosphate, with an
approximately 20-times higher affinity for cAMP (3,4). Through
hydrolysis of cAMP, PDE10A downregulates protein kinase A ac-
tivity, which relies on cAMP for activation and regulates the phos-
phorylation of various intracellular targets downstream of protein
kinase A such as DARPP-32 as an integrator of dopamine and glu-
tamate signals (5). This role in striatal signaling has made PDE10A
an enzyme of particular interest because it is likely involved in
several neuropsychiatric disorders. This hypothesis is supported
by preclinical studies with PDE10A inhibitors, showing that phar-
macologic inhibition of PDE10A leads to activation of medium
spiny neurons (MSNs) and alteration of behavioral aspects modu-
lated by the striatal circuit (6). Disruption of the conditioned avoid-
ance response, an established preclinical model for antipsychotic
activity, was observed after the administration of PDE10A inhibitor
TP-10 (7) and MP-10 (8), and reduced exploratory locomotor ac-
tivity was seen (7). Such pharmacologic alterations were not found
in PDE10A knockout mice (9). PDE10A inhibition may constitute
a new approach for the treatment of disorders with altered activity
of medium spiny neurons, such as schizophrenia (8), Huntington
disease (10), and addiction (11).
A suitable PDE10A tracer that allows in vivo quantification of
PDE10A would lead to a better understanding of the role of
PDE10A activity in health and disease, can be used as a tool for
early clinical evaluation of emerging PDE10A medication, and
may also present new diagnostic opportunities. Several attempts
to quantify PDE10A using PET have been recently published.
11C-MP-10 has been evaluated in nonhuman primates (2,12), but
although it showed good affinity and high selectivity for PDE10A,
a lipophilic radiolabeled metabolite hampered further human
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application. The preclinical evaluation of 11C-papaverine in rhe-
sus macaques showed low retention (13). We previously evalu-
ated 18F-JNJ41510417 in PDE10A knockout and wild-type mice
and in rodents (14). Although this tracer showed high selectivity
and affinity, in vivo brain kinetics were slow, hampering accu-
rate quantification. Therefore, it was decided to investigate other
candidates based on similar leads. 18F-JNJ-42259152, or 2-[[4-
[1-(2-18F-fluoroethyl)-4-(4-pyridinyl)-1H-pyrazol-3-yl]phenoxy]methyl]-
3,5-dimethyl-pyridine, is also an antagonist of PDE10A—with
a lower half-maximal inhibitory concentration of 1.6 nM (15),
a low polar surface area, and a plasma protein binding of 99.5%—
and is 1,000-fold more selective than for the other phosphodiesterase
enzymes (Janssen Research and Development, unpublished data,
2011). In humans, a first-in-man biodistribution and dosimetry study
showed that the tracer was safe and displayed promising kinetics for
further quantitative evaluation of PDE10A activity in the nigrostriatal
circuit (16).
The aim of this study was to perform full brain kinetic modeling
of 18F-JNJ-42259152 and study test–retest reproducibility in healthy
human volunteers. Additionally, we evaluated the simplified refer-
ence region model to investigate the possibility of noninvasively
quantifying PDE10A and reducing acquisition time to allow clinical
application in a variety of neuropsychiatric patient populations.
MATERIALS AND METHODS
Subjects
Healthy subjects aged 40–80 y were recruited for this monocentric,
academic study through advertisements in a local community news-
paper and on the departmental Web site. All subjects were screened
for neuropsychiatric and other medical disorders and were subjected
to a physical examination, blood and urine testing (including toxicol-
ogy for drugs), and structural brain MR imaging. Subjects who were
current users of any illicit drugs (including recreational use) or had
any history of drug or alcohol abuse were excluded. A history of to-
bacco use was also reason for exclusion unless the subject had com-
pletely stopped for at least 3 mo. No medication use was allowed.
In total, 12 healthy volunteers (5 men, 7 women) between the ages
of 42 and 77 y (mean age 6 SD, 57.8 6 10.3 y) were included. To
determine test–retest reliability over a period of weeks, 4 of these
subjects (2 men, 2 women; mean age6 SD, 61.56 13.9 y) underwent
a second PET scan. Written informed consent was obtained from all
the volunteers before participation. The study was approved by the
local Ethics Committee and performed in accordance to the latest
version of the World Medical Association Declaration of Helsinki.
Radiotracer Preparation
The precursor for tracer synthesis was obtained from Janssen Re-
search and Development. Radiolabeling was performed on-site using
1-18F-fluoro-2-bromoethane, which was distilled into the precursor so-
lution (containing Cs2CO3 in anhydrous dimethylformamide). The reaction
mixture was injected onto a high-performance liquid chromatography
(HPLC) system eluted with a mixture of sodium phosphate (0.01 M,
pH 2.2) and ethanol (15). The radiochemical purity was more than
95%, and specific activity was always higher than 100 GBq/mmol
(mean 6 SD, 222 6 156 GBq/mmol; range, 110–534 GBq/mmol).
In this study, the mean administered mass dose was 0.52 6 0.38 mg.
Pharmacologic Properties of JNJ-42259152
JNJ-42259152 is a potent and highly selective inhibitor of PDE10A.
JNJ-42259152 inhibits the cAMP-hydrolyzing activity of purified
recombinant PDE10A with potency pIC50 (known log of inhibition
constant at 50%) of 8.82 for the human enzyme. JNJ-42259152 is more
than 1,000-fold more selective for PDE10A, relative to all other human
phosphodiesterases. Various radioligand binding experiments (includ-
ing CEREP standard binding profiling) indicated that JNJ-42259152 at
a concentration of 10 mM did not show affinity for most of the human
receptors, ion channels, or transporters (Janssen Research and Devel-
opment, unpublished data, 2011). In vivo blocking and displacement
studies conducted in rats are the subject of a future preclinical eval-
uation study to be described elsewhere (17).
Imaging Procedure and Safety Assessments
All subjects were scanned on a HiRez Biograph 16 PET/CT camera
(Siemens) in 3-dimensional mode. For reasons of standardization,
subjects fasted for 4 h before PET. They received a fast bolus injection
of 173.5 6 6.3 MBq of 18F-JNJ-42259152. The dynamic PET brain
scan was initiated simultaneously with the radiotracer bolus injection
and consisted of 2 scanning segments. The first 90-min segment started
on tracer injection, and the second 30-min segment started at 105 min
after injection. Both segments were acquired in list-mode. A low-dose
CT scan (80-kV tube potential, 11 mAs) was obtained at the beginning
of both PET acquisition segments for attenuation correction.
Test–retest reproducibility was evaluated in 4 healthy volunteers.
The interval between scanning was 26.3 6 10.5 d.
For reconstruction, the first segment of each PET scan was rebinned
in 26 frames with progressively increasing frame durations (4 · 15, 4
· 60, 2 · 150, and 16 · 300 s), with a total duration of 90 min. The
second segment was rebinned in 6 frames of 300 s. All frames were
Fourier-rebinned and reconstructed using an ordered-subset expec-
tation maximization algorithm with 5 iterations and 8 subsets and
a uniform gaussian postsmoothing filter of 5 mm. The reconstructed
volume consisted of 81 slices of 2-mm thickness with a matrix size
of 128 · 128 and reconstructed pixel size of 2 mm. Emission data
were corrected for attenuation and scatter.
As part of the screening and for further anatomic coregistration with
PET to delineate volumes of interest, volumetric magnetization prepared
rapid acquisition gradient-echo T1 (repetition time, 0 ms; echo time, 4 ms;
flip angle, 12; inversion time, 300 ms; matrix, 256 · 256; 160 sagittal
contiguous slices of 1 mm) and standard T2 MR images were obtained.
To further assess the safety of 18F-JNJ-42259152 administrations,
before and after the PET acquisition a physical examination (including
blood pressure measurement and neurologic evaluation), laboratory
blood analyses (which included blood cell counts and liver and kidney
function tests), and electrocardiography were performed. An electro-
cardiogram and blood pressure measurements were also taken at other
predefined time points during the PET acquisition. All adverse expe-
riences were monitored during and immediately after the PET scan
(follow-up monitoring after the procedure comprised a telephone in-
terview at 24 and 14 d after scanning).
Plasma Input Curve and Metabolite Determinations
In all subjects, arterial and venous blood sampling was performed
manually through an arterial and venous cannula in the lower radial artery
and an antecubital vein, respectively (in the opposite arm of injection),
to determine the arterial input function curve and radiometabolite
fraction, determined both in arterial and venous blood. Per imaging
session, 2-mL arterial samples were drawn at the following times:
every 10 s for the first 100 s; at 120, 140, and 160 s after injection; and
at 3, 4, 5, 8, 10, 15, 20, 30, 40, 60, 90, and 120 min after injection.
Additional 5-mL blood samples (both arterial and venous) were drawn
at 5, 10, 20, 40, 90, and 120 min for metabolite measurement. All
samples were immediately placed on ice before analysis.
Blood samples were centrifuged for 10 min at 3,000 rotations
per minute. Authentic JNJ-42259152 (10 mg) was added to 0.8-mL of
plasma, and the mixture was then injected onto the HPLC system as
such. TheHPLCeluent was collected in 3 fractions: 2–5min, 10–12min
(metabolite fractions), and 13–16 min (parent fraction). A g-counter
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(1480 Automatic g-counter Wallac Wizard 3; PerkinElmer) was used
to measure the amount of radioactivity in each fraction.
Image Analysis and Kinetic Modeling
Motion correction was performed on the dynamic dataset using PMOD
(PMOD Inc.) (with sum of squared differences minimization algo-
rithm). The retest PET scan was rigidly registered to the first PET scan
and subsequently to the individual MR images (using normalized
mutual information and the first 16 image frames). Three-dimensional
volumes of interest were then manually delineated on individual MR
images for the following brain regions: caudate nucleus, putamen,
ventral striatum, substantia nigra, medial frontal cortex, thalamus, and
cerebellum. The latter 3 regions were considered as potential reference
regions with low PDE10A expression (1).
Tissue Distribution Volume and Metabolite Kinetics. The rate of
tracer metabolism was modeled by fitting (12 A)1 A · exp(2ln(2) ·
t/B) to the parent fraction fparent(t), where A (0 , A , 1) represents
a fast exponential metabolizing component with corresponding half-
life B. This way, a parent fraction estimate was available for each time
point of the arterial plasma activity samples. Using the corresponding
parent fraction estimates, we subdivided arterial plasma activity sam-
ples into activity values for the intact tracer fraction and a potential
metabolite fraction. This way, 2 arterial input functions were generated:
a metabolite-corrected arterial input function for modeling intact tracer
kinetics and a metabolite arterial input curve that can be used to model
metabolite kinetics.
To quantify regional tracer kinetics, total distribution volumes VT
(18) were estimated using a standard 1-tissue-compartment model (1TCM)
and 2-tissue-compartment model (2TCM) together with a radiometa-
bolite-corrected arterial input function. Time–activity curve data points
were weighted according to frame duration and radioactive decay.
Because initial results showed that a 2TCM was preferable to a
1TCM for describing tracer kinetics of brain regions with presumably
low PDE10A expression, we evaluated 3 possible assumptions to
further investigate these findings.
A first assumption was that a 2TCM was needed for appropriate
modeling of a small fraction of specific binding (2TCM[spec]). A sec-
ond hypothesis was that an aspecific tracer binding with slower kinet-
ics would require a 2TCM (2TCM[aspec]). Although both assumptions
use a mathematically equivalent 2TCM, boundary conditions in terms
of constraints applied to the 2TCM rate constants are different.
In the case of 2TCM[spec], the 2 compartments representing free tracer
and nonspecific binding of a 3-tissue-compartment model (3TCM)
were merged into 1 compartment representing the nondisplaceable dis-
tribution volume VND (Fig. 1). This simplification corresponds to the
most commonly used interpretation of 2TCM. Because specific bind-
ing is modeled by a separate compartment, VND corresponding to K1/k2
was estimated for the frontal cortex and considered constant for the
target and other potential reference regions. Other 2TCM parameters—
K1, k3, and k4, and therefore VS (distribution volume for specific bind-
ing)—were estimated independently for each brain region.
For the 2TCM[aspec] hypothesis, we used an approach as proposed by
Watabe (Hiroshi Watabe, written communication, 2012), where kinetic
behavior in the reference tissue is described on the basis of 2 tissue
compartments: one for free tracer and one for nonspecific binding. Basi-
cally, this means that 2 compartments of the 3TCM representing, respec-
tively, free tracer and specific binding, can be merged and the remaining
2TCM compartment represents nonspecific binding (Fig. 1). Assuming
that the amount of nonspecific binding in reference and target tissues was
the same, the distribution volume for the remaining tissue compartment
representing nonspecific binding was estimated for the frontal cortex and
set to this value for both target and other potential reference regions. No
further restrictions were applied to other 2TCM parameters K1, k2, and k3,
and therefore VND was estimated independently for each brain region.
A third hypothesis, the possible confounding effect of a brain-
penetrating radiometabolite on the quantification, was explored, where
one compartment accounts for intact tracer kinetics (1TCM[intact]) and
a second compartment describes the kinetics of a brain-entering radio-
metabolite. Intact tracer and metabolite kinetics were modeled using 2
separate parallel 1-tissue compartments with 2 separate parallel input
functions. The first 1-tissue compartment with the arterial intact tracer
input function described the specific and nonspecific binding of the
intact tracer (1TCM[intact]), and the other 1-tissue compartment with
the arterial metabolite input function was assumed to account for the
brain uptake of radiometabolite. Again, assuming the radiometabo-
lite fraction for the reference and target regions are the same, the
distribution volume of the radiometabolite VT,M was estimated for
the frontal cortex and set to the same value for the nigrostriatal tar-
get regions. VT,M determined with this model was compared with
the distribution volume for nonspecific binding VNS obtained with
2TCM[aspec] and with the fast metabolized fraction intact tracer in the
arterial blood compartment.
VT values for 1TCM, 2TCM, 2TCM[spec], and 2TCM[aspec] and the
corresponding plasma to tissue uptake rates K1 were evaluated. 1TCM,
2TCM, 2TCM[spec], and 2TCM[aspec] fittings were compared using
Akaike information criteria (AIC). 2TCM VT values were used as ref-
erence values for further correlation analysis to assess a possible sys-
tematic bias of the outcome measure.
Binding Potential (BPND) and Reference Tissue Models. Nondis-
placeable BPND using the simplified reference tissue model (SRTM)
(19) and multilinear reference tissue model (MRTM) (20) were eval-
uated with the frontal cortex as reference tissue. The frontal cortex
was considered the reference tissue of choice because it provided con-
sistently the lowest values for 2TCM VT, K1/k2, and (K1/k2) · (k3/k4)
when compared with other candidate reference tissues such as the thal-
amus and cerebellum (Fig. 2).
MRTM allows the fast generation of voxelwise parametric BPND
maps and therefore voxelwise statistical data comparison. For exploratory
FIGURE 1. Schematic overview of 2 possible simplifications of
3TCM. For 2TCM[aspec], compartments representing free and spe-
cific binding are merged, and remaining compartment represents
nonspecific binding. Latter nonspecific binding is assumed constant
for target and reference regions. For 2TCM[spec], compartments rep-
resenting free and nonspecific binding are merged to nondisplace-
able tissue compartment, and remaining compartment represents
specific binding. Former nondisplaceable compartment is assumed
constant for reference and target regions. CFT 5 free tracer con-
centration; CND 5 nondisplaceable tracer concentration; CNS 5
nonspecific tracer concentration; CP 5 plasma tracer concentration;
CS 5 specific tracer concentration.
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purposes, also the thalamus and cerebellum were considered as ref-
erence regions for SRTM and were compared with SRTM BPND and
AIC values using the frontal cortex.
For the target regions putamen, caudate nucleus, ventral striatum,
and substantia nigra, BPND values of the reference tissue models were
compared with BPND values of the full kinetic models 1TCM, 2TCM,
2TCM[spec], 2TCM[aspec], and 1TCM[intact]. In the case of 1TCM and
2TCM, BPND was estimated as the VT ratio relative to the frontal
cortex minus 1, and for 2TCM[spec], BPND was calculated as the VS
over VND ratio. For 2TCM[aspec], BPND values were calculated relative
to the frontal cortex while discarding the distribution volume for non-
specific binding. On the other hand, BPND values for 1TCM[intact] were
determined by taking into account only the intact tracer distribution
volume for target and reference tissue. In this way, the potential bias
due to nonspecific binding or a brain-penetrating radiometabolite was
avoided. 2TCM[aspec] BPND values were considered reference values
to allow correlation analysis and to assess possible over- or underes-
timation of the outcome measure.
Time Stability of Outcome Measures and Test–Retest Statistics. To
determine the stability of the 1TCM and 2TCM VT and SRTM and
MRTM BPND estimates as functions of the acquisition time, reduced
acquisition times of 90 and 60 min were evaluated and compared with
a 135-min acquisition interval. For each of the reduced acquisition
times, 1TCM and 2TCM AIC values were compared as well.
Test–retest variability (reproducibility) was assessed as the absolute
variability VAR defined as jx1 2 x2j/(x1 1 x2) · 200, where x
refers to the parameter of interest. Test–retest reliability was eval-
uated in terms of the intraclass correlation coefficient (ICC), defined
as (BSMS2WSMS)/(BSMS1WSMS), where BSMS is the between-
subject mean square and WSMS the within-subject mean square.
The ICC ranges from 0 to 1, with values closer to 1 indicating better
reliability, which means that most variance is due to between-subject
rather than within-subject variation.
Statistical Analysis
Statistical analysis was performed using Prism software (version
5.0; GraphPad Software). Parameters of interest were compared using
1-way repeated-measure ANOVA including Bonferroni multiple-
comparison tests. When appropriate, a 2-tailed paired Student t test
was used. Correlation analysis was performed using a Spearman r
correlation coefficient. A P value of 0.05 was considered a threshold
criterion of statistical significance. Values are represented as mean6 SD
unless otherwise stated. The ratio between parameters was determined as
the slope of linear regression analysis with the intercept set to zero.
RESULTS
Brain Uptake and Plasma Metabolites
Figure 3A shows orthogonal late standardized uptake value
images (averaged over 60–90 min) of 18F-JNJ-42259152 in a rep-
resentative subject. Figure 3B shows the corresponding time–
activity curves for the striatal regions, substantia nigra, thalamus,
cerebellum, and medial frontal cortex. 18F-JNJ-42259152 exhibits
relatively fast brain kinetics for the striatal regions, with a time to
peak after bolus injection of 10–15 min, followed by a moderately
fast washout. No subjective or objective adverse events during or
after tracer administration were reported in any of the subjects.
Metabolite analysis identified 2 metabolites in plasma after
40 min, 1 polar and 1 nonpolar metabolite, through cleavage of the
18F-containing pyridine ring with fenol formation, both unlikely to
pass the blood–brain-barrier. The fraction of radiometabolites of
18F-JNJ-42259152 in arterial plasma, as percentage of the intact
fraction, is given in Figure 4. A fraction of 51.9% 6 9.8% was
metabolized, with a half-life of 18.7 6 7.6 min constituting a fast
metabolism component, whereas the remaining fraction was me-
tabolized slowly, resulting in an approximately 50% fraction of
intact tracer after 2 h.
FIGURE 2. Overview of VT, K1/k2, and (K1/k2) · (k3/k4) for 2TCM for candidate reference tissue regions thalamus, frontal cortex, and
cerebellum. ctx 5 cortex.
FIGURE 3. (A) Average standardized uptake value image (SUV)
(averaged over 60- to 90-min interval) for 18F-JNJ-42259152 in hu-
man brain. (B) Time–activity curves for putamen, caudate nucleus,
ventral striatum, substantia nigra, thalamus, frontal cortex, cerebel-
lum, and white matter. ctx 5 cortex; ventr 5 ventral.
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Kinetic Modeling
Tissue Distribution Volume and Metabolite Kinetics. An over-
view of average VT for the considered models and brain re-
gions is given in Figure 5. The fraction nondisplaceable bind-
ing VND and specific binding VS is given for 2TCM and
2TCM[spec] whereas for 2TCM[aspec] VT is subdivided in the
fraction free and specifically bound tracer VFT1S and non-
specific binding VNS. A significant difference between VT values
was found for all pairs of models, except between 2TCM and
2TCM[aspec].
When the distribution volume of the intact tracer determined
using 1TCM[intact] and the distribution volume of the free and
specifically bound tracer VFT1S determined using 2TCM[aspec]
were compared, no significant difference was found. For
1TCM[intact], the VT,M was 0.16 6 0.05, and VNS for 2TCM[aspec]
was 0.12 6 0.06. There was a significant correlation between
the 2TCM[aspec] VNS and 1TCM[intact] VT,M values (r 5 0.79) and
between 2TCM[aspec] VNS and the fraction intact tracer A that
was metabolized in the arterial blood compartment (r 5 0.74).
K1 values for the different models are summarized in Figure 6, and
K1, k2, k3, and k4 values are presented in Table 1 for 1TCM and 2TCM.
K1 values differed significantly between all model pairs, except for the
pairs 2TCM and 2TCM[aspec] and 2TCM[aspec] and 1TCM[intact].
Average AIC values for 1TCM, 2TCM, 2TCM[spec], and
2TCM[aspec] were, respectively, 261.1 6 15.0, 243.7 6 21.0,
249.9 6 21.4, and 245.7 6 23.9. The AIC for the 1TCM was
significantly higher than for the 2TCM. Furthermore, significant
differences were found between the 2TCMs except between
2TCM and 2TCM[aspec].
Table 2 gives an overview of the correlations between 2TCM
VT and other models per brain region. The global VT ratios are
given in Table 3. For all target regions, the correlation between
models was excellent.
BPND and Reference Tissue Models. An overview of average
BPND for the considered models and brain target regions is given
in Figure 7. No significant BPND differences were found among
2TCM, SRTM, and MRTM or between 2TCM[aspec] and 1TCM[in-
tact]. All other BPND differences were significant. Table 2 summa-
rizes the Spearman correlation coefficients separately for each
target region, and Table 3 gives overall BPND ratios, both using
2TCM[aspec] BPND as a reference value.
When the thalamus and cerebellum were considered as
reference tissues for SRTM, average BPND values for the putamen,
caudate nucleus, ventral striatum, and substantia nigra were, re-
spectively, 2.78 6 0.47, 1.35 6 0.31, 0.77 6 0.23, and 0.22 6
0.10 for the thalamus and, respectively, 2.91 6 0.44, 1.43 6 0.36,
0.84 6 0.34, and 0.26 6 0.12 for the cerebellum. Compared with
the corresponding values 3.45 6 0.43, 1.78 6 0.35, 1.10 6 0.31,
and 0.44 6 0.09 for the frontal cortex, SRTM BPND values refer-
enced to the thalamus and cerebellum both differed significantly
from those referenced to the frontal cortex whereas no significant
difference was found between the thalamus and cerebellum. SRTM
BPND values using the thalamus and cerebellum relate to SRTM
BPND values using the frontal cortex by a factor 0.79 and 0.83,
respectively. In terms of correlation with SRTM BPND using the
frontal cortex, spearman r correlation coefficients of SRTM BPND
using thalamus and cerebellum were, respectively, 0.83 and 0.76
for the putamen, 0.92 and 0.80 for the caudate nucleus, 0.81 and
0.87 for the ventral striatum, and 0.64 and
0.52 for the substantia nigra. Overall corre-
lation coefficient for both the thalamus and
the cerebellum was 0.98. All correlations
were significant except the SRTM BPND
for the substantia nigra using the cerebel-
lum. To compare reference regions in
terms of model fitting, SRTM AIC values
using the thalamus, frontal cortex, and cer-
ebellum were, respectively, 239.1 6 17.4,
240.5 6 16.7, and 240.8 6 16.3 and not
significantly different.
Time Stability and Test–Retest of VT and
BPND. The time stability of VT for 1TCM
and 2TCM and of BPND for SRTM and
MRTM are given in Figure 8. 1TCM and
2TCM VT values for the 135- and 90-min
acquisition times were not significantly
different contrary to 60-min VT values,
which were significantly lower than those
for the 135-min acquisition time. 2TCM
was the preferred model for the 135-min
FIGURE 4. Fraction of intact 18F-JNJ-42259152 tracer in arterial
plasma as function of time after injection.
FIGURE 5. Obtained cerebral VT for 18F-JNJ-42259152 with 1TCM, 2TCM, 2TCM with con-
stant nondisplaceable distribution volume VND and variable distribution volume for specific
binding VS (2TCM[spec]), 2TCM with constant nonspecific distribution volume VNS and variable
distribution volume for free tracer and specific binding Vft1s (2TCM[aspec]), and 1TCM taking into
account brain-penetrating radiometabolite (1TCM[intact]) using 135-min acquisition time (n5 12).
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acquisition time, with a significantly lower AIC and significantly
higher VT than 1TCM. Although 2TCM AIC (204.0 6 19.3) is still
significantly lower than 1TCM AIC (212.7 6 12.1) for the 90-min
acquisition time, the situation is reversed for the 60-min acquisi-
tion time where—based on the lower AIC—1TCM (64.0 6 15.4)
is the preferred model over 2TCM (69.9 6 15.5).
For MRTM and SRTM, BPND values were slightly but signifi-
cantly higher for the 90- and 60-min acquisition times than for the
135-min acquisition time. However, global correlations between
BPND values for the shorter times and the 135-min acquisition
time were significant and excellent for both reference tissue mod-
els (Spearman r $ 0.94).
Region-specific test–retest statistics for VT and BPND are sum-
marized in Table 4. No significant differences between the VT
values of different compartmental models were found in terms
of variability or ICC. In addition, no significantly different vari-
ability or ICCs were found for BPND values determined with
SRTM and MRTM.
DISCUSSION
The regional in vivo distribution of 18F-JNJ-42259152 in the
brain was concordant with the known distribution of PDE10A
from preclinical and histopathologic findings, with the highest
activity in the putamen and in second or-
der the caudate nucleus, ventral striatum,
and substantia nigra. Cortical and cerebel-
lar activity was more than 10-fold lower
than activity in the striatum. Previous stud-
ies using in situ hybridization and quanti-
tative polymerase chain reaction have
shown that levels in the cortex, cerebellum,
and thalamus are 10- to 40-fold lower than
in the striatum (1,10). This finding indi-
cates that, although expression levels out-
side the nigrostriatal region are low, they
are not negligible and a careful evaluation
of their use as a reference region is there-
fore warranted.
Tracer kinetics were first assessed using
a standard 1TCM and 2TCM. Our findings
indicated that the 2TCM is the preferred
method to describe tracer kinetics, both
for target and for potential reference re-
gions. To determine whether 2TCM was
more appropriate for potential reference
regions because of low PDE10A expression in these regions, we
constrained the distribution volume for nondisplaceable binding
VND for all brain regions to a constant value determined using the
frontal cortex. In this way, VT differences between regions could
be induced only by differences in specific binding. However, VT
values of this constrained 2TCM[spec] approach were significantly
different from unconstrained 2TCM fittings. Second, we assumed
the presence of a nonspecific binding tissue compartment with
slower tracer kinetics next to the free and specific binding tissue
compartment with distribution volume VFT1S. Distribution vol-
ume for nonspecific binding VNS was estimated using a frontal
cortex time–activity curve and constrained to this value for the
other brain regions. The VT values of this constrained 2TCM[aspec]
approach were not significantly different from unconstrained
2TCM fittings. Moreover, AIC values of the 2TCM[aspec] fittings
were not significantly different from those of the 2TCM fittings.
To determine whether this extra compartment was needed to
model the nonspecific binding of a potential brain-penetrating
radiometabolite instead of the intact tracer, we also modeled intact
tracer kinetics with metabolite kinetics for the target and reference
regions using 2 separate parallel 1-tissue compartments with 2
separate arterial input functions (i.e., intact tracer and radiometa-
bolite input function [1TCM[intact]]). For this approach, the tissue
VT,M was estimated using the frontal cortex and was constrained to
TABLE 1
Overview of Rate Constants of 1TCM and 2TCM for 18F-JNJ-42259152 and Different Brain Regions
Model Putamen Caudate nucleus Ventral striatum Substantia nigra Thalamus Frontal cortex Cerebellum Global
1TCM
K1 0.038 6 0.006 0.031 6 0.006 0.027 6 0.006 0.016 6 0.003 0.021 6 0.005 0.017 6 0.004 0.031 6 0.007 0.026 6 0.009
k2 0.027 6 0.004 0.037 6 0.005 0.045 6 0.006 0.044 6 0.008 0.075 6 0.015 0.073 6 0.013 0.117 6 0.032 0.060 6 0.032
2TCM
K1 0.044 6 0.006 0.033 6 0.007 0.030 6 0.007 0.022 6 0.004 0.028 6 0.005 0.022 6 0.004 0.038 6 0.009 0.031 6 0.010
k2 0.050 6 0.017 0.046 6 0.011 0.063 6 0.015 0.094 6 0.015 0.136 6 0.010 0.131 6 0.011 0.182 6 0.038 0.100 6 0.051
k3 0.035 6 0.047 0.005 6 0.006 0.010 6 0.009 0.026 6 0.012 0.012 6 0.004 0.010 6 0.004 0.008 6 0.004 0.015 6 0.021
k4 0.044 6 0.028 0.029 6 0.043 0.028 6 0.023 0.035 6 0.012 0.019 6 0.007 0.015 6 0.007 0.014 6 0.007 0.026 6 0.024
Data are mean 6 SD.
FIGURE 6. Plasma–to–tissue tracer uptake rate (K1) for 18F-JNJ-42259152 for 1TCM,
2TCM, 2TCM with constant nondisplaceable distribution volume VND and variable distribu-
tion volume for specific binding VS (2TCM[spec]), 2TCM with constant nonspecific distribution
volume VNS and variable distribution volume for free tracer and specific binding VFT1S
(2TCM[aspec]), and 1TCM taking into account brain-penetrating radiometabolite (1TCM[intact])
using 135-min acquisition time (n 5 12).
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this value for the other brain regions, to be able to estimate the
distribution volume of the intact tracer for each brain region. No
significant difference was observed between intact tracer VT and
VF1S. Furthermore, significant correlations were found between
VT,M and VNS and between VNS and the fraction of metabolites in
the arterial plasma compartment. Because there was evidence
from preclinical experiments of a brain-penetrating radiometabo-
lite in rodents (17), the current findings can be compatible also
with a radiometabolite that is entering the brain, which could be
a confounding factor for tracer quantification. Nevertheless, these
findings also proved that both approaches were essentially the
same and that metabolite kinetics could be modeled as nonspecific
binding using only an intact tracer arterial input function.
Although possibly biased by a brain-penetrating radiometabo-
lite, significant VT correlations were found with the standard
1TCM and 2TCM approach for all regions. For the target regions,
correlations were still significant between VT using a 2TCM ap-
proach and VT of the intact tracer, demonstrating that in any case
there is a reproducible bias of the tentative radiometabolite on
tracer quantification.
Plasma–to–tissue uptake rates K1 (Table 2) are relatively low,
with significantly lower values due to poorer fittings for the 1TCM
than 2TCM approach. These K1 values are comparable to tracers
such as 18F-fluorodopa (population average K1, 0.03 mL/g/min)
(21), meaning that tracer uptake is perfusion independent. Al-
though in general this can have the possible disadvantage of low
signal because of the limited tracer uptake, the current spatial
restriction to the striatum, with excellent signal-to-background
ratio, indicates that an accurate quantification is feasible.
Because 2TCM[aspec] accounts for nonspecific binding of either
intact tracer or radiometabolite and provided similar VT and AIC
values as unconstrained 2TCM fittings, BPND calculated as the
ratio VFT1S minus 1 relative to the frontal cortex was used as a
reference value. As expected, no significant difference was found
between these BPND 2TCM[aspec] reference values and BPND cal-
culated as the 1TCM[intact] tracer VT ratio minus 1 relative to the
frontal cortex. Although SRTM and MRTM BPND values were
significantly lower than the reference values because the radio-
metabolite uptake or nonspecific binding is included when deter-
mining the reference tissue BPND values, SRTM and MRTM BPND
showed good correlations with the 2TCM[aspec] reference values
for the different target regions. Only the SRTM BPND correlation
for the putamen was borderline not significant, with a P value of
0.055.
Concerning the use of the thalamus and cerebellum as reference
tissues for SRTM, both regions proved to be acceptable alter-
natives, with BPND values that correlated significantly with those
for the frontal cortex (except for the substantia nigra), although
BPND values were significantly different.
For 1TCM, VT was stable down to 60 min, with a significant
negative bias of 5.5%. For 2TCM, a more pronounced significant
negative bias of 14% was noticed. 2TCM fittings became less
stable for reduced acquisition times whereas for the 60-min ac-
quisition time, differences between 1TCM and 2TCM VT became
TABLE 2
Correlation Coefficients for Different Models for 18F-JNJ-42259152 Versus 2TCM
Spearman correlation coefficients
Model Putamen Caudate nucleus Ventral striatum Substantia nigra Thalamus Frontal cortex Cerebellum Global
VT
1TCM 1.00 0.83 0.90 0.91 0.85 0.85 0.84 0.96
2TCM[spec] 0.99 0.83 0.90 0.97 0.97 1.00 0.97 0.99
2TCM[aspec] 0.96 0.79 0.75 0.97 0.95 1.00 0.78 0.98
1TCM[intact] 0.99 0.86 0.89 0.73 0.62 (0.54) 0.76 0.93
BPND
1TCM 0.73 0.79 0.65 0.60 0.98
2TCM (0.51) (0.34) (0.36) 0.94 0.94
2TCM[spec] 0.95 0.90 0.95 (0.42) 0.98
1TCM[intact] 0.96 0.86 0.85 0.72 0.99
SRTM[FCx] (0.57) 0.82 0.70 0.64 0.97
MRTM[FCx] 0.61 0.81 0.71 0.64 0.97
Acquisition interval of 135 min was used (n 5 12). Values in parentheses indicate nonsignificant correlations (P $ 0.05). For reference
tissue models, frontal cortex was used as reference region.
SRTM[FCx] 5 SRTM with frontal cortex (FCx) as reference tissue; MRTM with frontal cortex (FCx) as reference tissue.
TABLE 3
Global Ratio of VT and BPND for 18F-JNJ-42259152
Ratio type 1TCM 2TCM 2TCM[spec] 2TCM[aspec] 1TCM[intact] SRTM[FCx] MRTM[FCx]
VT 0.93 1.0 0.95 0.98 0.82 — —
BPND 0.73 0.56 1.10 1.0 0.98 0.48 0.49
For reference tissue models, frontal cortex was used as reference region. Acquisition interval of 135 min was used (n 5 12).
SRTM[FCx] 5 SRTM with frontal cortex (FCx) as reference tissue; MRTM with frontal cortex (FCx) as reference tissue.
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insignificant and 1TCM was the preferred model with the lower
AIC. These findings are in agreement with the assumption that
2TCM accounts for a compartment with slow kinetics representing
either nonspecific tracer binding or radiometabolite brain uptake.
When the small positive bias for SRTM and MRTM (both 4%
for 90 min and 5% for 60 min) is taken into account, we can
conclude that 60- to 90-min dynamic acquisition should be suf-
ficient to allow accurate quantification with SRTM or MRTM
using the frontal cortex as a reference tissue.
In terms of long-term (weeks) test–retest, all models presented
similar statistics, with repeatability values of 5%–20% for VT and
5%–12% for BPND. Although ICC values were within acceptable
range, overall variability was relatively high and should be con-
sidered when comparing intersubject VT and BPND values. ICC
values were lower for the reference tissue models than for the
compartmental models because of the lower between-subject var-
iability. Variability was higher for compartmental models than for
reference tissue models, probably because of added variability in-
duced by arterial sampling and radiometabolite fraction corrections.
Concerning the limitations of the study and possible future
perspectives, it needs to be emphasized that in the current design
there was no independent reference available to provide an objec-
tive assessment of quantitative accuracy of the all proposed kinetic
models. However, 3 different scenarios were considered: a brain-
penetrating metabolite, nonspecific binding with slower kinetics,
and a fraction of specific binding (because low nonzero PDE10A
expression has been documented in histologic postmortem studies)
in candidate reference regions such as the frontal cortex. In-
dependent of the real underlying physiologic phenomenon, the
kinetic models that take into account these different scenarios
provide highly correlated quantitative endpoints that are also
highly correlated with the standard and more straightforward
reference tissue models. Therefore, future PET dose–occupancy
studies (enzyme-blocking studies) are needed to allow a better
estimate of the nondisplaceable binding of the tracer and to con-
firm or exclude one of the before-men-
tioned scenarios. PET dose–occupancy
studies will also provide a better insight
into the regional and interindividual dif-
ferences of nondisplaceable binding and
justify use of reference tissue models as
quantitative models. Furthermore, the
small extraction fraction of the tracer with
high affinity and accumulation in the stria-
tum might cause some concern that delivery
could be rate-limiting. This issue needs to
be addressed in future studies and by com-
parison to other radioligands that are cur-
rently under development.
CONCLUSION
We successfully characterized kinetic
modeling of the PDE10A tracer 18F-JNJ-
42259152 in the human brain. 18F-JNJ-
42259152 currently is the only published
PDE10A PET tracer with good character-
istics for human studies. A potential meta-
bolite contribution in brain uptake cannot
be excluded, although nonspecific bind-
ing of the intact tracer can be an alterna-
tive explanation for the observed kinetic behavior. In any case,
this contribution is small and reproducible. Therefore, a 90-min
dynamic acquisition and a reference tissue approach with the
frontal cortex as reference tissue provides a reproducible and ac-
curate estimation of BPND, allowing more feasible quantitative
studies in neuropsychiatric study populations.
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2TCM, BPND was estimated as ratio minus 1. For 2TCM with constant nondisplaceable
distribution volume VND and variable distribution volume for specific binding VS (2TCM[spec]),
BPND was calculated ratio of VS over VND. For 2TCM with constant nonspecific distribution
volume VND and variable distribution volume for free tracer and specific binding VFT1S
(2TCM[aspec]), BPND values were calculated discarding nonspecific binding. BPND values
for 1TCM taking into account brain-penetrating radiometabolite (1TCM[intact]) consider only
intact tracer distribution volume. BPND for SRTM and MRTM are reported as well. All values
are estimated for 135-min acquisition time (n 5 12).
FIGURE 8. Induced bias and variance of reduced acquisition
times of 60 and 90 min for 18F-JNJ-42259152, relative to acquisition
time of 135 min. This is shown both for VT of 1TCM and 2TCM and
for BPND values of SRTM and MRTM using frontal cortex as refer-
ence tissue.
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